An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Omalizumab (Xolair): Treatment of Adults and Adolescents (12 Years of Age and above) with Chronic Idiopathic Urticaria [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.
Uncertainty regarding the parameters chosen for the base-case analysis was addressed by the manufacturer using a one-way deterministic sensitivity analysis and a probabilistic sensitivity analysis. For the three scenarios, the following parameters had the greatest impact on the ICUR (± 25%): time horizon, perspective, natural remission rate, and utility weights.
The probabilistic sensitivity analysis showed that in scenario 1, in approximately 31% of iterations, the ICUR was below a willingness-to-pay threshold of $50,000 per QALY.
In scenario 3, the probabilistic sensitivity analysis showed that at a willingness-to-pay threshold of $50,000, omalizumab 300 mg added on as a second-line drug to H1 antihistamines had a 1.6% probability of being cost-effective compared with H1 antihistamines alone.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
